Despite current challenges in the life science real estate market, we continue to benefit from a high quality tenant base with 57% of our annual rental revenue coming from investment grade, our publicly traded large cap tenants, long remaining lease terms of 7.7 years, average rent steps approaching 3% on 97% of our leases and strong adjusted EBITDA margins of 65% for the quarter. We continue to focus on the successful reduction in management of general and administrative expenses. We remain on track with our guidance range about 134 to 154 million for 2026. ? And our trailing 12-month GA is a percentage of net operating income through 3Q26 of 7.5% is almost half of the average for all SP 500 REITs over the last few years of 14.3%. Realized gains included in FFO per share diluted as adjusted from our venture investments were 16 million for 3Q26 and 44.5 million for the first three quarters of 2026. ? We lowered our guidance range for realized investment gains by 10 million at the midpoint from 75 million to 65 million due to certain transactions being pushed out into 2027. We expect average real estate basis capitalized to reach a bottom for 2026 in the fourth quarter, ranging from $3.4 billion to $4.9 billion, which is a 40 to 60% decline from the basis that was capitalized for all of 2025. This is generally consistent with a significant 40% reduction in non income producing assets as a percentage of gross assets, which has declined from 20% at the end of 2024 to 12% as of 3Q26. Capitalized interest for 3Q26 was 62.9 million, was down 11 million from the prior quarter, primarily driven by significant deliveries from the pipeline, coupled redevelopment projects that reached milestones and were paused. We expect a further decline in capitalized interest in the fourth quarter, driven by by two large projects designated as held for sale at September 30th, coupled with significant deliveries from the pipeline in 3Q26, including the 199,000 square foot delivered in note to Novo and Nordisk for its RD center at 60 Sylvan on our wealth and megacampus. We continue to execute and favorably resolve our development and redevelopment pipeline. From 4Q25 to 3Q26, the pipeline has shrunk by more than 50% from 3.6 million square feet to 1.6 million square feet. This included three major accomplishments during 3Q26, including the following. First, we delivered 529,000 square feet of development and redevelopment space. It was 84% occupied, and we'll generate 40 million of annual net operat income. Second, we entered into a contract to sell most of our remaining investment in our development project at 421 Park Drive in the Fenway with a 4Q26 anticipated closing date. And third, with respect to our 311 Arsenal Street project in Watertown, we've executed leases of 67,000 square feet and 101,000 square feet of leases are under negotiation, primarily with advanced technology tenants, which has allowed us to pivot to a lower cost advanced technology execution and will reduce future construction needs by approximately $220 million over the next few years. ? As of 3Q26, we have 906,000 square feet of development and redevelopment projects under construction and expected to stabilize through 2028, which are 77% leased or negotiating. In addition, we have 667,000 square feet primarily related to two projects, for which we are evaluating the business and financial strategy. The first is 40 Sylvan Road, which is located in our Walthamega megacampus. We continue to believe this project would be attractive to advanced technology tenants that may find the campus as well as certain elements of the building attractive and may not require a conversion to lab. The second ? is 3,000 Minuteman Road, which is located in our Andover mega campus. The campus is very attractive to advanced technology tenants, as evidenced by the 160,000 square foot lease we executed for an adjacent building on this campus and Q26. If we complete significant advanced technology leases, we may place all or some of these spaces into the operating pool, which may reduce operating occupancy in the near term, but more importantly, will reduce our future capital needs and generate near term revenue upon delivery. We continue to make very good progress in raising capital, with $1.7 billion completed since June 30th, including the $1 billion junior subordinated notes offering completed in August. The 7.25% junior subordinated notes offering had several important benefits, including the following four key features. First, the rating agencies ascribe 50% equity credit to the notes, which will help us achieve our 2026 leverage goal. Second, it provided an implied cost of equity capital superior to the cost of issuing common equity as well as non-course stabilized operating asset sales. Third, it reduces our 2026 target for asset sales and near-term reliance on joint ventures. And fourth, it represents a fixed cost of capital for at least five years with significant flexibility to refinance thereafter. We are highly focused on and expect to meet our $1.9 billion midpoint for dispositions and sales of partial interest. Our team is making good progress with $717 million completed, including $242 million of non-corrent land dispositions ? and a $475 million sale of a partial interest related to our campus point megacampus. In addition, we have $355 million under contract and subject to non refundable deposits, an additional $1.5 billion of dispositions and sales of partial interest with signed letters of intent or in late stage negotiations. Included in the $1.5 billion of pending transactions is one large joint venture for which we are actively engaged. The aggregate sum of the completed and pending transactions is $2.6 billion, which exceeds the midpoint of our 2026 guidance by approximately $720 million, which may provide us the opportunity to potentially close certain transactions ? in 2026, but defer the capital into 2027. There are three key points on the campus point joint venture transaction I'd like to highlight. First, Alexander will control and consolidate the joint venture. Second, the joint venture contains a waterfall distribution model that shifts just distributions over time. But at a minimum, we expect the joint venture to make distributions to our new partner equivalent to at least 5.5% of their initial $475 million contribution in year one and beyond. And third, our partner has a put right exercisable after seven years, and we may settle that amount in cash or shares of common stock at our election. In connection with our disposition program, we did recognize impairments of real estate of $638 million during the quarter, of which substantially all of this amount is related to developments in process, land, or properties that were laboratory conversion opportunities. The two largest impairments made up 75% of the total balance and included the following. First, we are under contract to sell to an institutional user substantially all our remaining space at our 421 Park Drive development project located in the Fenway. This project was acquired in January 2021 and was under construction. As a result of the expected sale, this removes the overhang on leaseup of this project, and the buyer will take on the cost to complete the interior lab improvements, which we estimate to be approximately $136 million.
Passages & reports (37) 13:38 Despite current challenges in the life science real estate market, we continue to benefit … Report 13:58 3% on 97% of our leases and strong adjusted EBITDA margins of 65% for the quarter. We cont… Report 14:18 154 million for 2026. Report 14:21 And Report 14:21 our trailing 12-month GA is a percentage of net operating income through 3Q26 of 7.5% is a… Report 14:41 adjusted from our venture investments were 16 million for 3Q26 and 44.5 million for the fi… Report 14:51 We Report 14:51 lowered our guidance range for realized investment gains by 10 million at the midpoint fro… Report 15:11 quarter, ranging from $3.4 billion to $4.9 billion, which is a 40 to 60% decline from the … Report 15:31 from 20% at the end of 2024 to 12% as of 3Q26. Capitalized interest for 3Q26 was 62.9 mill… Report 15:51 redevelopment projects that reached milestones and were paused. We expect a further declin… Report 16:10 square foot delivered in note to Novo and Nordisk for its RD center at 60 Sylvan on our we… Report 16:31 from 3.6 million square feet to 1.6 million square feet. This included three major accompl… Report 16:51 operat income. Second, we entered into a contract to sell most of our remaining investment… Report 17:10 67,000 square feet and 101,000 square feet of leases are under negotiation, primarily with… Report 17:30 over the next few years. Report 17:33 As Report 17:33 of 3Q26, we have 906,000 square feet of development and redevelopment projects under const… Report 17:53 we are evaluating the business and financial strategy. The first is 40 Sylvan Road, which … Report 18:12 lab. The second Report 18:14 is Report 18:14 3,000 Minuteman Road, which is located in our Andover mega campus. The campus is very attr… Report 18:34 we may place all or some of these spaces into the operating pool, which may reduce operati… Report 18:54 30th, including the $1 billion junior subordinated notes offering completed in August. The… Report 19:13 will help us achieve our 2026 leverage goal. Second, it provided an implied cost of equity… Report 19:33 ventures. And fourth, it represents a fixed cost of capital for at least five years with s… Report 19:53 progress with $717 million completed, including $242 million of non-corrent land dispositi… Report 20:00 and Report 20:00 a $475 million sale of a partial interest related to our campus point megacampus. In addit… Report 20:21 Included in the $1.5 billion of pending transactions is one large joint venture for which … Report 20:40 potentially close certain transactions Report 20:42 in Report 20:43 2026, but defer the capital into 2027. There are three key points on the campus point join… Report 21:03 over time. But at a minimum, we expect the joint venture to make distributions to our new … Report 21:22 that amount in cash or shares of common stock at our election. In connection with our disp… Report 21:42 properties that were laboratory conversion opportunities. The two largest impairments made… Report 22:02 Fenway. This project was acquired in January 2021 and was under construction. As a result … Report